1-347-509-6837 contact us about us group subscriptions affiliate program careers sitemap rss feed terms of use privacy market data sources © 2025 seeking alpha
Shares of ImmunityBio (NASDAQ:IBRX) have lost nearly 90% of their value since March 9th completion of 100% stock-for-stock merger with NantKwest last year. For year-to-date 2022, shares have lost one-third of their value despite recent FDA acceptance of BLA filing for Join 500+ inves...